LNF-1901

N/A

Report date: 2025/07/26 20:00:09

Base Information

Drug NameLNF-1901
Drug Alias NameLNF-1901LNF1901
ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsAnti-CD40T lymphocytes stimulants
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesLunan Pharmaceutical Group Co
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesLunan Pharmaceutical Group CoShandong New Time Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A